You are viewing an inactive listing
This listing is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active listings please search here

Clinical Trial 44131

NATIONWIDE


Summary:

TYME Pancreatic Cancer Clinical Trial

TYME is an emerging biotechnology company developing next generation Cancer Metabolism-Based Therapies (CMBTs™) for patients with advanced cancers.

The TYME-88-Panc pivotal trial applies the latest advances in the field of cancer metabolism by evaluating the efficacy and safety of an oral investigational compound that targets the metabolic mechanisms of the disease at its source. A prospective, open label pivotal trial in metastatic pancreatic cancer for patients who have failed two lines of any prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate.

  • Now recruiting patients with metastatic pancreatic cancer
  • Multiple locations
  • Eligibility requirements will be discussed with a study representative


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.